MUCOLYTIC THERAPY IN PEDIATRICS: MYTHS AND REALITY
Main Article Content
Abstract
The article discusses the problem of treating respiratory tract diseases in children, accompanied by the development of mucostasis and discrinia. In particular, mucolytic therapy with an original drug of the N-acetylcysteine group, which has both direct mucolytic, antioxidant and anti-inflammatory effects, is presented in detail. These properties are especially important in chronic bronchopulmonary pathology and explain its high effectiveness. Various dosage forms allow the doctor to use the drug in patients of different ages, including newborns and infants.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Soroka N.D. Mucolytic therapy of protracted variants of the course of respiratory diseases in children // Issues of modern pediatrics. - 2018. - T. 7, No. 4. - P. 111–114.
Balyasinskaya G.L., Bogomilsky M.R., Lyumanova S.R. Experience in the use of topical mucolytic drugs in the treatment of rhinosinusitis in children // Pediatrics. — 2016. — No. 6. — P. 1–4.
Bronchitis in children: A manual for doctors / Ed. VC. Tatochenko. - M., 2014. - 89 p.
Belousov Yu.B., Omelyanovsky V.V. Clinical pharmacology of respiratory diseases in children: A guide for doctors. - M., 2016. - 176 p.
Practical pulmonology of childhood (reference book) / Ed. VC. Tatochenko. - M., 2020. - P. 26–29, 57–62, 183–192.